TNF inhibitor

For many women, the journey to motherhood brings a sense of anticipation and joy. However, for those with rheumatoid arthritis (RA), this journey presents unique challenges. Women with RA often face…

The ORAL surveillance trial raised safety concerns that the janus kinase inhibitor (JAKi) tofacitinib was associated with an increased incidence of cancer and major adverse cardiovascular events…

We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents –…

The ACR Convergence 2024 meeting provided its attendees with vast information about disease pathophysiology, diagnosis and treatment covering both clinical and basic sciences. One of the hot topics…

The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. This study comparing the…

Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.Statins and major adverse cardiovascular…

This year at #ACR24, emulation trials are being presented.Are these ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized…

At last year’s ACR, I shared about the early clinical trial data on bimekizumab in psoriatic arthritis. Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A…

ACR 2024 starts tomorrow. Here are a few previews of abstracts to be presented, along with my recommendations of sessions you don’t want to miss.Previews:Abstract Number: 2527 Efficacy and…